伴同性诊断市场规模、份额及成长分析（按产品、技术、适应症、样本类型、最终用户和地区）－2025 年至 2032 年产业预测

2023 年伴同性诊断市场规模价值 69 亿美元，预计将从 2024 年的 77.6 亿美元增长到 2032 年的 199.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 12.5%。

伴同性诊断市场正在经历显着增长，受癌症发病率上升和精准医疗需求增加的推动。这些测试对于确定相关生物疗法的安全性和有效性至关重要，尤其是在肿瘤学领域。随着基因组学、蛋白质组学和代谢组学分析的不断发展，对伴同性诊断的需求呈指数级增长，以确定适当的治疗方法并预测有利的结果。此外，个人化医疗的出现凸显了这些诊断在个人化治疗方法中的重要作用。政府措施的支持，尤其是 FDA 和 EMA 的支持，以及有利的监管指导正在加速市场发展势头。简化的核准流程将提高伴同性诊断的可用性，促进改善治疗结果和及时的患者照护。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 技术分析
• 案例研究
• 客户和购买标准分析

伴同性诊断市场规模（依产品/服务划分）及复合年增长率（2025-2032）

• 市场概览
• 检测套件试剂
• 设备和系统
• 软体和服务

伴同性诊断市场规模（依技术及复合年增长率） (2025-2032)

• 市场概览
• 聚合酵素链锁反应
• 原位杂交
• 次世代定序
• 免疫组织化学
• 其他技术

伴同性诊断市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概览
• 癌症
  • 肺癌
  • 乳癌
  • 血癌
  • 大肠直肠癌
  • 其他癌症
• 神经系统疾病
• 心血管疾病
• 感染疾病
• 其他适应症

伴同性诊断市场规模（按样本类型和复合年增长率）（2025-2032）

• 市场概览
• 组织样本
• 血液样本
• 其他样本类型

伴同性诊断市场规模（依最终用户划分）及复合年增长率（2025-2032）

• 市场概览
• 製药和生物技术公司
• 参考实验室
• 合约研究组织
• 其他最终用户

伴同性诊断市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Abbott（United States）
• IDVet（France）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Agilent Technologies, Inc.（United States）
• AniCell Biotech（United States）
• Illumina, Inc.（United States）
• Guardant Health（United States）
• Thermo Fisher Scientific Inc.（United States）
• BIOMERIEUX（France）
• NEOGEN Corporation（United States）
• Zoetis Inc.（United States）
• Myriad Genetics, Inc.（United States）
• Virbac SA（France）

结论和建议

Companion Diagnostics Market size was valued at USD 6.9 billion in 2023 and is poised to grow from USD 7.76 billion in 2024 to USD 19.92 billion by 2032, growing at a CAGR of 12.5% during the forecast period (2025-2032).

The companion diagnostic market is experiencing significant growth, driven by the rising incidence of cancer and the increasing demand for precision medicine. These tests are critical for determining the safe and effective administration of related biological treatments, particularly in oncology. As genomic, proteomic, and metabolomic profiling continues to evolve, the need for companion diagnostics to identify appropriate therapies and predict positive outcomes is surging. Furthermore, the advent of personalized medication highlights the essential role of these diagnostics in individualized treatment approaches. Support from government initiatives and favorable regulatory guidance, particularly from entities like the FDA and EMA, is accelerating market momentum. Streamlined approval processes enhance the availability of companion diagnostics, promoting improved treatment efficacy and timely patient care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Companion Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Companion Diagnostics Market Segments Analysis

Global Companion Diagnostics Market is segmented by Product, Technology, Indication, Sample Type, End User and region. Based on Product, the market is segmented into Assays, Kits, And Reagents, Instruments & Systems and Software & Services. Based on Technology, the market is segmented into Polymerase Chain Reaction, In Situ Hybridization, Next-Generation Sequencing, Immunohistochemistry and Other Technologies. Based on Indication, the market is segmented into Cancer, Neurological Diseases, Cardiovascular Diseases, Infectious Diseases and Other Indications. Based on Sample Type, the market is segmented into Tissue Samples, Blood Samples and Other Sample Types. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Reference Laboratories, Contract Research Organizations and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Companion Diagnostics Market

In recent years, there has been a significant rise in cancer cases, which has intensified the demand for effective companion diagnostics (CDx) assays. This increasing incidence heightens the necessity for genetic testing, which equips healthcare professionals with critical insights to tailor treatment plans specifically for their patients' unique cancer profiles. Consequently, the surging prevalence of cancer is driving the market for CDx products, as these assays are essential in delivering precise and personalized therapeutic approaches. Thus, the urgent need for innovative and efficient CDx solutions has become a prominent market driver in the face of escalating cancer diagnoses.

Restraints in the Companion Diagnostics Market

The Companion Diagnostics market faces significant restraints due to the considerable financial investment required for regulatory compliance, validation, and clinical trials. These high expenses can pose a significant challenge for smaller companies, potentially hindering their ability to enter and compete in the market. Furthermore, ambiguous and varied reimbursement policies surrounding companion diagnostics further complicate market expansion. The complexity of navigating these policies can deter new entrants, creating additional barriers for growth and limiting access to advancements in personalized medicine. As a result, these factors collectively contribute to a restrained landscape within the Companion Diagnostics sector.

Market Trends of the Companion Diagnostics Market

The Companion Diagnostics market is poised for significant growth driven by innovations in Next-Generation Sequencing (NGS) technology. NGS enables comprehensive gene profiling in surgically removed tumors, facilitating the identification of cancer-associated genes and enhancing personalized treatment strategies. The transition of NGS from research to clinical applications, as highlighted by a recent CDC report, underscores its increasing importance in precision medicine. As its technological capabilities expand and adoption in clinical settings accelerates, NGS is expected to play a pivotal role in improving patient outcomes, ultimately fueling market growth and solidifying its place in oncological diagnostics and treatment planning.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies
• Customer And Buying Criteria Analysis

Global Companion Diagnostics Market Size by Product & Service & CAGR (2025-2032)

• Market Overview
• Assays, Kits, And Reagents
• Instruments & Systems
• Software & Services

Global Companion Diagnostics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Polymerase Chain Reaction
• In Situ Hybridization
• Next-Generation Sequencing
• Immunohistochemistry
• Other Technologies

Global Companion Diagnostics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Cancer
  • Lung Cancer
  • Breast Cancer
  • Blood Cancer
  • Colorectal Cancer
  • Other Cancers
• Neurological Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Other Indications

Global Companion Diagnostics Market Size by Sample Type & CAGR (2025-2032)

• Market Overview
• Tissue Samples
• Blood Samples
• Other Sample Types

Global Companion Diagnostics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Reference Laboratories
• Contract Research Organizations
• Other End Users

Global Companion Diagnostics Market Size & CAGR (2025-2032)

• North America (Product & Service, Technology, Indication, Sample Type, End User)
  • US
  • Canada
• Europe (Product & Service, Technology, Indication, Sample Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product & Service, Technology, Indication, Sample Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product & Service, Technology, Indication, Sample Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product & Service, Technology, Indication, Sample Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDVet (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AniCell Biotech (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOMERIEUX (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NEOGEN Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations